Fibroblast growth factor - ViaCell

Drug Profile

Fibroblast growth factor - ViaCell

Alternative Names: dFGF - ViaCell; Dimerised fibroblast growth factor - ViaCell

Latest Information Update: 09 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer ViaCell
  • Class Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 09 Apr 2008 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 08 Nov 2005 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 02 Sep 2002 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top